![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 17, 2019 5:28:18 PM
I have talked to some other posters about why we don't have any other analyst coverage for CVM besides Zacks, which is paid for by CVM by the way. It hasn't sat well with us. It has given us reservations. Why, so far into our study and with things looking seemingly good do we not have any other analysts initiating coverage on our good little company? It gives us pause. Do they know something we don't? So I did a little bit of research. Here is what I found. Hint, it is seemingly positive.
Link: https://www.theglobeandmail.com/globe-investor/a-stock-with-no-analysts-can-bring-big-rewards-risks/article26909894/
"As a general rule, a company covered by lots of analysts will tend to be very fairly valued, with little upside beyond the overall market's move," he says. "So if you're going to be a do-it-yourself investor looking for big gains, you need to look for gems that are covered by few or no analysts."
If a company has earnings, a good balance sheet and is trading at a reasonable price but has no analyst coverage, the odds are that it's cheap," he says. "Analysts can easily be wrong, and sometimes get too close to management and can be prone to 'groupthink,'" he says.
He also notes it can be more difficult for companies without analyst coverage to get their stories out when things are going well. While the returns on investments in overlooked companies can be large, there are certainly significant risks. Stocks that don't have analyst coverage can stay overlooked for quite some time – especially by institutional investors whose buying has the greatest impact on stock prices.
Some observers feel the investment dealers have other motives for their coverage decisions. Since the most profitable part of their business is investment banking (helping companies go public, issue more stock and make acquisitions), there is a possible incentive to offer companies favourable analyst coverage in return for investment banking business. "Analysts cover companies that need financing because ultimately a dealer earns money raising money for companies," says Mr. Taylor. "But the best companies don't need money. They generate enough cash to fund their stocks." Mr. Gallander has the same suspicion. "They often choose companies that generate fees for them," he says. "That makes them less than impartial."
Ultimately, whether a company is covered by analysts or not, the best rule for investors is to rely on their own research. "It really helps if people can understand financial statements and financial ratios," says Mr. Gallander. "Do a ton of reading and analysis.Going to annual company meetings and getting a better feel for the company's management can also be extremely helpful. As well, sticking to sectors that are easy to understand or you have some expertise in can help you with your research.
Link: [/size]https://www.zacks.com/education/articles.php?id=57
According to Multex, there were 8,911 companies traded on U.S. markets last year. Roughly 3,100 of those companies, or about 35%, are followed by at least one analyst. In other words, 65% of publicly traded companies in the U.S. are not followed by a single analyst. With that many uncovered stocks, you can bet there are many neglected ones out there. So how does one measure the “neglect-factor” of a stock?
This brings us to the question of why greater analyst coverage is good for a neglected stock. The reason is simply that not enough managers are aware the stock even exists to cause the stock’s price to accurately reflect the true earnings potential of the company. Increasing analyst coverage is great because analysts almost always initiate coverage with a positive recommendation. This makes sense because there isn’t much point in writing a research report on an obscure company if it is a dog.
Analysts neglect stocks for a variety of reasons, but the main one is that there are no banking fees at stake. A little, unknown stock is much less likely to price a secondary offering or announce a merger than some blue chip such as General Electric. As we all know, financial companies are in it to make money as well, and there is not too much money to be made by covering obscure stocks that won’t generate much revenue for the analyst’s firm.
Recent CVM News
- CEL-SCI Appoints Robert Watson as Chairperson of the Board • Business Wire • 07/08/2024 01:15:00 PM
- CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population • Business Wire • 06/18/2024 12:00:00 PM
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor • Business Wire • 06/06/2024 11:00:00 AM
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM